3 Ustekinumab Biosimilars Launch on US Market

The year 2025 marks a transformative shift in the pharmaceutical landscape as multiple low-cost biosimilars enter the U.S. market to compete with the high-revenue drug Stelara. Following a series of legal delays and patent settlements, several pharmaceutical companies have launched alternative treatments for chronic inflammatory conditions, such as Crohn’s disease and plaque psoriasis. These new options aim to expand patient access and reduce financial burdens through competitive pricing and strategic insurance coverage agreements. Furthermore, the introduction of interchangeable designations will eventually allow pharmacists to substitute these more affordable versions automatically, streamlining the delivery of care for millions of Americans.